(Total Views: 453)
Posted On: 10/01/2025 12:54:22 AM
Post# of 157554
Basket trial was 2021. This should get you there surfrebel.
https://clinicaltrials.gov/study/NCT04504942
Verified 2021-09 by CytoDyn, Inc.
Last known status was: Active, not recruiting
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov ID NCT04504942
Sponsor CytoDyn, Inc.
Information provided by CytoDyn, Inc. (Responsible Party)
Last Update Posted 2022-07
-——————-
28 patients in retrospective look at mTNBC, some of which date back and were included in basket trial, others were EIND. So you kinda have the 28 right. But there were 30 in the actual basket trial.
5 in CRC? Not yet, headed that way. More are onboarding now. At 5 we may get a DSMB decision to increase dosage to 700mg, also a dosage escalation data point that was established as safe with minor diarrhea effects due to extra proteins in system around 2021,2022.
——————
Nice that a 6th mTNBC patient is exhibiting elevated PD-L1 and company is treating as well as including this patients progress in current shareholder comms. So the 5 ladies of LL might well become 6.
https://clinicaltrials.gov/study/NCT04504942
Verified 2021-09 by CytoDyn, Inc.
Last known status was: Active, not recruiting
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov ID NCT04504942
Sponsor CytoDyn, Inc.
Information provided by CytoDyn, Inc. (Responsible Party)
Last Update Posted 2022-07
-——————-
28 patients in retrospective look at mTNBC, some of which date back and were included in basket trial, others were EIND. So you kinda have the 28 right. But there were 30 in the actual basket trial.
5 in CRC? Not yet, headed that way. More are onboarding now. At 5 we may get a DSMB decision to increase dosage to 700mg, also a dosage escalation data point that was established as safe with minor diarrhea effects due to extra proteins in system around 2021,2022.
——————
Nice that a 6th mTNBC patient is exhibiting elevated PD-L1 and company is treating as well as including this patients progress in current shareholder comms. So the 5 ladies of LL might well become 6.
(5)
(0)
